集团最近透过若干投资基金或特殊目的公司(SPV)架构取得合共约570万美元的私募股权投资，以期将该 等私募股权投资用于日后的RWA代币化目的。该等私募股权包括间接持有字节跳动、Kraken及eSelf AI 等知名科技公司的权益。 消息面上，德林控股发布公告，公司继续积极制订及扩展其数字资产策略，专注于字节跳动有限公司 (字节跳动)、Payward,Inc.(Kraken)及E-Self.AI Ltd.(eSelf AI)等知名科技公司私募股权的代币化，及持有 德林大厦及Animoca Brands权益的有限合伙基金的代币化。 德林控股(01709)涨超5%，截至发稿，涨4.91%，报3.42港元，成交额1.75亿港元。 ...

中联发展控股(00264)发布公告，内容有关收购目标公司(NVTH Limited)20%已发行股本的须予披露交 易。 董事会宣布，公司仍在与相关订约方进行磋商，并认为收购事项将不会依照协议所载的条款及条件进 行，且协议将于2025年9月30日失效。 此外，在考虑与战略伙伴的合作时，董事会进一步宣布，于2025年9月26日，公司与NVTHK Limited(战 略伙伴)订立了一份不具法律约束力的意向书，据此，公司拟透过与战略伙伴的战略合作，探索数字资 产及Web3行业的业务发展机会。 战略伙伴为一家在香港注册成立的有限公司。战略伙伴主要从事提供以下服务：基于区块链的RWA代 币化技术基础设施平台;连接传统金融与去中心化Web3市场的机构级交易和流动性解决方案;以及为资本 市场参与者提供以合规为重点的生态系统服务。战略伙伴致力于建立连接传统金融与Web3生态系统的 基础设施，并将自身定位为塑造数位资本市场格局的先驱。 董事会一直致力于寻求新业务和创造价值的机会，并适时拓展公司的营运及投资范围。集团正积极探索 创新及新业务机会，以加强产品开发并多元化收入来源。董事会认为透过潜在合作有助加快投入数字资 产及Web3 ...

香港在Web3及数字资产领域正取得重大进展。香港政府发布的《数位资产发展政策声明2.0》中，强调 了香港致力于成为值得信赖且富有创新精神的全球数位资产中心的决心。此外，香港最近颁布的《稳定 币条例》已于2025年8月1日起生效，为香港受监管的稳定币活动引入发牌制度，旨在增强市场信心并与 全球标准接轨。监于香港有利于Web3及金融科技产业的持续发展，集团对RWA代币化相关业务的潜力 持乐观态度。 在考虑与战略伙伴的合作时，董事会进一步宣布，于2025年9月26日，公司与NVTHK Limited("战略伙 伴")订立了一份不具法律约束力的意向书，据此，公司拟透过与战略伙伴的战略合作，探索数字资产及 Web3行业的业务发展机会。 格隆汇9月26日丨中联发展控股(00264.HK)公告，为了实现业务多元化及拓展，公司正积极考虑开展 Web3及数字资产业务，当中包括：(1)组建自有团队，探索涉足Web3及数字资产领域的可能性；及／或 (2)寻求与在Web3及现实世界资产("RWA")业务领域拥有丰富经验的战略合作伙伴合作。其将透过进行 业务可行性研究及招募专业人才，开展相关业务。 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負 責，對其準確性或完整性亦不發表任何聲明，並明確表示，概不因本公告全部 或部分內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 自願公告 本公告由中聯發展控股集團有限公司（「本公司」，連同其附屬公司，統稱 「本集團」）董事（「董事」）會（「董事會」）自願作出。 茲提述本公司日期為二零二五年八月二十一日、二零二五年九月十日及二零二 五年九月十一日之公告（「該等公告」），內容有關（其中包括）有關收購目 標公司 20%已發行股本之須予披露交易。除另有指明外，本公告所用詞彙與該 等公告所界定者具有相同涵義。 董事會宣佈，本公司仍在與相關訂約方進行磋商，並認為收購事項將不會依照 協議所載的條款及條件進行，且協議將於二零二五年九月三十日失效。 為了實現業務多元化及拓展，本公司正積極考慮開展 Web3 及數字資產業務，當 中包括：(1)組建自有團隊，探索涉足 Web3 及數字資產領域的可能性；及／或 (2)尋求與在 Web3 及現實世界資產（「RWA」）業務領域擁有豐富經驗的戰略 合作夥伴合作。其將透過進行業務可行性研究及招募專業人才，開展相關業 ...

据悉，若代币发行成功，未来的融资所得将用于加速多项创新肿瘤抗体项目的临床及临床前研发。创胜 集团董事会主席钱雪明博士表示："我们专注创新药研发，尤其是在治疗肿瘤、骨质疏松和慢性肾病领 域。做药是一个漫长、高风险、高投入的过程，我们需要大量资金。通过华检医疗的链上RWA数字平 台，我们可以将创新药管线的IP装入美国SPV进行新型融资，这为我们提供了全新的资金渠道。" 消息面上，创胜集团与华检医疗(01931)就潜在的创新药管线资产RWA代币化相关事项订立战略合作协 议。创胜方将其旗下六个核心创新药管线资产（TST003, TST005, TST786, TST105, TST106及TST013） 整合至其美国实体，并利用华检医疗构建的ETHK全球创新药知识产权RWA交易所进行潜在RWA代币化 合作。 智通财经APP获悉，创胜集团-B(06628)尾盘涨逾10%，截至发稿，涨8.31%，报4.82港元，成交额 2072.25万港元。 ...

Group 1 - The cryptocurrency sector is experiencing significant declines, with notable drops in share prices for companies such as OKC Cloud Chain (down 5.13% to HKD 0.37), Guotai Junan International (down 4.51% to HKD 4.87), and OSL Group (down 4.45% to HKD 15.25) [1] - The China Securities Regulatory Commission (CSRC) has informally requested certain brokerages to suspend their real-world asset (RWA) tokenization activities in Hong Kong to enhance risk management and ensure that issuances are backed by real assets [1] - Hong Kong is actively working to establish itself as a digital asset hub, while China has prohibited cryptocurrency trading and mining since 2021 and recently instructed major brokerages to halt research on stablecoins [1]

Group 1 - A new asset paradigm is emerging globally, driven by the tokenization of Real World Assets (RWA) using blockchain technology, enabling continuous global liquidity and financing [1][17] - The ETHK Building, launched by Huajian Medical in Nanjing, is the world's first RWA technology base, marking a significant step in the large-scale implementation of RWA technology in China [3][8] - The ETHK Building spans approximately 70,000 square meters, with the main building covering 35,000 square meters, making it the largest and most comprehensive RWA research and innovation base globally [3][7] Group 2 - The establishment of the ETHK Building addresses the dual challenges of technical infrastructure and regulatory frameworks that have hindered the large-scale implementation of RWA [3][8] - The building is designed as a dual-purpose infrastructure, serving as both a center for R&D and a base for trusted technology development and output [3][7] - The facility is expected to gather over 5,000 technical experts and engineers, forming one of the strongest RWA research teams globally [7] Group 3 - Huajian Medical's "ETHK Global RWA Trading - Exchange within an Exchange" model aims to fill the service gap in China's RWA market, providing a comprehensive solution for asset selection, structural design, compliance issuance, and liquidity management [8][9] - This model is particularly valuable in the healthcare sector, facilitating innovative financing for drug development and global market expansion [9][10] Group 4 - Huajian Medical has entered a phase of scaling its "Exchange within an Exchange" model, signing strategic cooperation agreements with four key partners across various sectors, including pharmaceuticals and legal compliance [9][10] - The collaboration with Chuangsheng Group involves the tokenization of innovative drug pipeline assets, with a total valuation exceeding $1.5 billion, representing cutting-edge research in cancer treatment [10] Group 5 - The launch of the RWA Protocol White Paper addresses key challenges in the current financial system, focusing on creating a foundational protocol for the issuance and trading of real-world assets [10][15] - The RWA Protocol aims to enhance settlement efficiency, transparency, and compliance in capital markets, facilitating cross-border asset allocation [15] Group 6 - Huajian Medical's strategy aligns with national policies promoting the market-oriented operation and securitization of intellectual property, as highlighted in recent government initiatives [16] - The global RWA market is projected to reach $16.1 trillion by 2030, representing 10% of global GDP, indicating significant growth potential [16] Group 7 - The completion of the ETHK Building symbolizes a new financial paradigm and showcases China's innovative capabilities in integrating blockchain with the real economy [17] - As more assets are tokenized through RWA, a more open, efficient, and inclusive global asset allocation era is anticipated, with Huajian Medical leading the charge [17]

Core Insights - The strategic cooperation agreement between Huajian Medical and Transcenta Holding aims to explore the potential RWA tokenization of six core innovative drug pipeline assets valued at over $1.5 billion, representing cutting-edge research in the global oncology treatment field [1][2] - This collaboration marks a significant milestone in the integration of technology and finance, as it represents the first issuance of high-value innovative drug intellectual property assets in RWA form in the capital market [1][2] Summary by Sections Strategic Cooperation - Huajian Medical and its subsidiaries have entered into a strategic cooperation agreement with Transcenta Holding and its subsidiaries to explore RWA tokenization of innovative drug pipeline assets [1] - The six core assets involved are TST003, TST005, TST786, TST105, TST106, and TST013, which are integrated into Transcenta Oncology Inc. in the U.S. [1] RWA Tokenization Benefits - The RWA tokenization aims to lock in the research value of high-value pipelines, allowing issuers to efficiently activate top pipeline assets at various clinical stages without diluting equity [2] - It provides a new channel for global capital allocation, offering professional investors a transparent, compliant, and efficient opportunity to invest in cutting-edge innovative drug intellectual property assets [2] - The innovative financing model is expected to accelerate the development of advanced therapies, ultimately benefiting global patients and addressing urgent unmet medical needs [2] Future Growth and Collaboration - The collaboration is anticipated to generate significant synergies, injecting strong momentum into the sustainable business growth and financial performance of the group [2] - The group will work closely with Transcenta to ensure the successful implementation of the project to high standards [2]

智通财经APP讯，华检医疗(01931)发布公告，公司及公司附属公司ETHK Inc及ETHK HOLDINGS LIMITED与创胜集团医药有限公司Transcenta Holding Limited(创胜集团，股票代号：06628.HK)及其附 属公司Transcenta Oncology Inc. (US)(统称创胜方)就潜在的创新药管线资产RWA代币化相关事项订立战 略合作协议。 据此，创胜方将其旗下六个核心创新药管线资产(即TST003,TST005,TST786,TST105,TST106及TST013) 整合至其美国实体Transcenta Oncology Inc. (US)，并利用集团专业构建的ETHK全球创新药知识产权 RWA交易所，与华检医疗就资产的潜在RWA代币化进行合作。该等资产总估值超过15亿美元，代表全 球肿瘤治疗领域最前沿的研发方向与高技术壁垒。 集团将为该等管线资产提供涵盖数字化发起、可信上链、合规发行及流动性对接的全流程技术解决方 案。本次合作标志着全球首批高价值创新药知识产权资产以RWA形式正式在资本市场发售/推出，是一 项标志着科技与金融深度融合的里程碑事件。 提供全球 ...

Core Viewpoint - The strategic cooperation agreement between Huajian Medical and Chuangsheng Group-B marks a significant milestone in the integration of technology and finance, focusing on the tokenization of innovative drug pipeline assets valued at over $1.5 billion [1] Group 1: Strategic Cooperation - Huajian Medical and its subsidiaries ETHK Inc and ETHK HOLDINGS LIMITED have entered into a strategic cooperation agreement with Chuangsheng Group-B and its subsidiary Transcenta Oncology Inc. [1] - The agreement involves the integration of six core innovative drug pipeline assets into Transcenta Oncology Inc. [1] Group 2: Asset Valuation and Technology Solutions - The total valuation of the integrated assets exceeds $1.5 billion, representing cutting-edge research directions and high technical barriers in the global oncology treatment field [1] - The group will provide a comprehensive technical solution covering digital initiation, trusted on-chain processes, compliant issuance, and liquidity connection for these pipeline assets [1] Group 3: Market Impact - This cooperation signifies the official launch of high-value innovative drug intellectual property assets in the capital market in the form of RWA, highlighting a milestone event in the deep integration of technology and finance [1]